Humanized 40H3 Antibody
Summary:
The NCI seeks research co-development partners or licensees for monoclonal antibodies that specifically target cancer-expressed EGFR.
Methods for Treating or Ameliorating Fibrosis by Inhibiting the Interaction between IL-21 Receptor (IL-21R) and IL-21
This invention includes methods for treating or ameliorating fibrosis by inhibiting the interaction between IL-21 Receptor (IL-21R) and IL-21 using either anti-IL-21R monoclonal antibodies (or binding fragments of anti-IL-21R mAbs), anti-IL-21 monoclonal antibodies (or binding fragments of anti-IL-21 mAbs) or soluble IL-21R (or binding fragments of IL-21R). It is believed that the TH2 immune response, induced by IL-21, plays a major role in the in the pathogenesis of tissue fibrosis.
Novel Antigen for Use as Vaccine Against Nematode Infection
This invention describes a new vaccine against Strongyoides stercoralis, which establishes a parasitic infection that affects an estimated 100-200 million people worldwide. The potential for fatal disease associated with S. stercoralis infection and the difficulty in treating hyperinfection underscores the need for prophylactic vaccines against the disease. This vaccine uses S. stercoralis immunoreactive antigen (SsIR); a novel antigen capable of providing 70-90 % protection for mice immunized with the antigen.
Recombinant NIE Antigen from Strongyloides stercoralis
Strongyloides stercoralis is an intestinal nematode endemic that affects an estimated 30 to 100 million people worldwide. Many of these individuals may be asymptomatic for decades. The present invention discloses a NIE recombinant antigen that can be used in improved assays and diagnostics for S. stercoralis infection. The NIE antigen is the only one that is non-cross-reactive with sera from humans with other related filaria infections. The NIE antigen can be utilized as a skin test antigen for immediate hypersensitivity as well as for use in ELISA or other assays.
Recombinant LL-SXP-1 and Plasmid Encoding LL-SXP-1 for the Immunodiagnosis of Loa Loa
A Loa loa specific antigen that can be used as the basis of an immunoassay for the diagnosis of Loa loa infection.
Antigens for Use in Loa Loa Microfilariae Quantitative Immunoassays
Loa loa microfilarial-specific peptide sequences that could be used as a research material as well as for development of immunoassays for detection of Loa loa microfilaremia.
Polyclonal and Monoclonal Antibodies to Human Eosinophil Major Basic Protein, Eosinophil Peroxidase, Eosinophil Cationic Protein, and Eosinophil-Derived Neurotoxin
Reagents particularly useful in configuring multiplex assays for simultaneous measurement and quantification of multiple eosinophil granule proteins and for immunohistochemistry. Ultimately these reagents may be used as diagnostics for many eosinophil-mediated disorders.
Antibodies with Potent and Broad Neutralizing Activity against Antigenically Diverse and Highly Transmissible SARS-CoV-2 Variants
Emergence of highly transmissible SARS-CoV-2 variants of concern that are resistant to current therapeutic antibodies highlights the need for continuing discovery of broadly reactive antibodies.
Surgical Tool for Sub-retinal Tissue Implantation
The accurate placement of transplanted tissue at a precise position in the retina is difficult but critical for a successful implementation of an ocular surgical intervention.
ELISA-Based Biodosimeter for Measuring and Quantifying DNA Damage
Summary:
The National Cancer Institute (NCI) seeks co-development partners and/or licensees to further develop a novel ELISA-based biodosimeter.